| RS1603634749 |
DMD
|
Health Risk |
Likely pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS1603635326 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS1603635331 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS1603635949 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS1603635950 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS1603635953 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS1603636515 |
DMD
|
Health Risk |
Pathogenic |
— |
| RS1603636537 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Becker muscular dystrophy |
| RS1603636541 |
DMD
|
Health Risk |
Pathogenic/Likely pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS1603636710 |
DMD
|
Health Risk |
Likely pathogenic |
Muscular dystrophy, Muscular dystrophy |
| RS1603639319 |
KCNMA1
|
Health Risk |
Likely pathogenic |
— |
| RS16052 |
CACNA1A
|
Health Risk |
Conflicting classifications of pathogenicity |
Developmental and epileptic encephalopathy, 42 |
| RS16054 |
CACNA1A
|
Health Risk |
Conflicting classifications of pathogenicity |
Spinocerebellar ataxia type 6, Spinocerebellar ataxia type 6 |
| RS1611115 |
DBH
|
Health Risk |
association |
Dopamine beta-hydroxylase polymorphism, Dopamine beta-hydroxylase polymorphism |
| RS1616940 |
PKD1
|
Health Risk |
Conflicting classifications of pathogenicity |
Polycystic kidney disease 3 with or without polycystic liver disease, Polycystic kidney disease |
| RS1617629 |
DSC2
|
Health Risk |
Conflicting classifications of pathogenicity |
Arrhythmogenic right ventricular dysplasia 11, Cardiomyopathy |
| RS1617640 |
EPO
|
Health Risk |
risk factor |
Microvascular complications of diabetes, susceptibility to |
| RS1621962 |
NPC1
|
Health Risk |
Conflicting classifications of pathogenicity |
Niemann-Pick disease, type C1 |
| RS1638362423 |
HMGCL
|
Health Risk |
Pathogenic/Likely pathogenic |
Deficiency of hydroxymethylglutaryl-CoA lyase, Deficiency of hydroxymethylglutaryl-CoA lyase |
| RS1638446514 |
HMGCL
|
Health Risk |
Likely pathogenic |
Deficiency of hydroxymethylglutaryl-CoA lyase, Deficiency of hydroxymethylglutaryl-CoA lyase |
| RS1638446662 |
HMGCL
|
Health Risk |
Likely pathogenic |
Deficiency of hydroxymethylglutaryl-CoA lyase, Deficiency of hydroxymethylglutaryl-CoA lyase |
| RS1638447240 |
HMGCL
|
Health Risk |
Pathogenic |
Deficiency of hydroxymethylglutaryl-CoA lyase, Deficiency of hydroxymethylglutaryl-CoA lyase |
| RS1638539773 |
B3GALT6
|
Health Risk |
Pathogenic |
Ehlers-Danlos syndrome, spondylodysplastic type |
| RS1638540007 |
B3GALT6
|
Health Risk |
Pathogenic |
Ehlers-Danlos syndrome, spondylodysplastic type |
| RS1638543931 |
KIF1B
|
Health Risk |
Conflicting classifications of pathogenicity |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS1638552845 |
B3GALT6
|
Health Risk |
Conflicting classifications of pathogenicity |
Spondyloepimetaphyseal dysplasia with joint laxity, type 1 |
| RS1638559065 |
VWA1
|
Health Risk |
Likely pathogenic |
Neuromuscular disease, Neuromuscular disease |
| RS1638566519 |
B3GALT6
|
Health Risk |
Pathogenic/Likely pathogenic |
Ehlers-Danlos syndrome, spondylodysplastic type |
| RS1638569809 |
SKI
|
Health Risk |
Pathogenic |
Shprintzen-Goldberg syndrome, Shprintzen-Goldberg syndrome |
| RS1638575128 |
HMGCL
|
Health Risk |
Pathogenic |
Deficiency of hydroxymethylglutaryl-CoA lyase, Deficiency of hydroxymethylglutaryl-CoA lyase |
| RS1638575413 |
HMGCL
|
Health Risk |
Pathogenic |
Deficiency of hydroxymethylglutaryl-CoA lyase, Deficiency of hydroxymethylglutaryl-CoA lyase |
| RS1638612983 |
VWA1
|
Health Risk |
Likely pathogenic |
— |
| RS1638619737 |
HMGCL
|
Health Risk |
Likely pathogenic |
Deficiency of hydroxymethylglutaryl-CoA lyase, Deficiency of hydroxymethylglutaryl-CoA lyase |
| RS1638620864 |
HMGCL
|
Health Risk |
Likely pathogenic |
Deficiency of hydroxymethylglutaryl-CoA lyase, Deficiency of hydroxymethylglutaryl-CoA lyase |
| RS1638632303 |
HMGCL
|
Health Risk |
Pathogenic/Likely pathogenic |
Deficiency of hydroxymethylglutaryl-CoA lyase, Deficiency of hydroxymethylglutaryl-CoA lyase |
| RS1638698732 |
HMGCL
|
Health Risk |
Likely pathogenic |
Deficiency of hydroxymethylglutaryl-CoA lyase, Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency |
| RS1638698938 |
HMGCL
|
Health Risk |
Pathogenic |
Deficiency of hydroxymethylglutaryl-CoA lyase, Deficiency of hydroxymethylglutaryl-CoA lyase |
| RS1638699083 |
HMGCL
|
Health Risk |
Likely pathogenic |
Deficiency of hydroxymethylglutaryl-CoA lyase, Deficiency of hydroxymethylglutaryl-CoA lyase |
| RS1638701269 |
HMGCL
|
Health Risk |
Likely pathogenic |
Deficiency of hydroxymethylglutaryl-CoA lyase, Deficiency of hydroxymethylglutaryl-CoA lyase |
| RS1638734576 |
MFN2
|
Health Risk |
Conflicting classifications of pathogenicity |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS1638739035 |
MFN2
|
Health Risk |
Pathogenic/Likely pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS1638739623 |
MFN2
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS1638740322 |
MFN2
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS1638772305 |
YARS1
|
Health Risk |
Likely pathogenic |
Neurologic, endocrine |
| RS1638957324 |
MFN2
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS1638959411 |
AK2
|
Health Risk |
Likely pathogenic |
Severe combined immunodeficiency disease, Severe combined immunodeficiency disease |
| RS1638960014 |
GALE
|
Health Risk |
Likely pathogenic |
UDPglucose-4-epimerase deficiency, UDPglucose-4-epimerase deficiency |
| RS1638974195 |
GALE
|
Health Risk |
Pathogenic |
UDPglucose-4-epimerase deficiency, UDPglucose-4-epimerase deficiency |
| RS1638975235 |
AK2
|
Health Risk |
Likely pathogenic |
Severe combined immunodeficiency disease, Severe combined immunodeficiency disease |
| RS1638981096 |
GALE
|
Health Risk |
Pathogenic |
UDPglucose-4-epimerase deficiency, UDPglucose-4-epimerase deficiency |
| RS1638984968 |
GALE
|
Health Risk |
Pathogenic |
UDPglucose-4-epimerase deficiency, UDPglucose-4-epimerase deficiency |
| RS1639038679 |
GALE
|
Health Risk |
Pathogenic |
UDPglucose-4-epimerase deficiency, UDPglucose-4-epimerase deficiency |
| RS1639043704 |
MFN2
|
Health Risk |
Pathogenic/Likely pathogenic |
Charcot-Marie-Tooth disease type 2, Neuropathy |
| RS1639045345 |
MFN2
|
Health Risk |
Pathogenic/Likely pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2A2 |
| RS1639045962 |
MFN2
|
Health Risk |
Conflicting classifications of pathogenicity |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2A2 |
| RS1639047697 |
MFN2
|
Health Risk |
Likely pathogenic |
Charcot-Marie-Tooth disease type 2A2, Charcot-Marie-Tooth disease type 2A2 |
| RS1639048523 |
MFN2
|
Health Risk |
Likely pathogenic |
Charcot-Marie-Tooth disease type 2, Uterine corpus endometrial carcinoma |
| RS1639091509 |
AGMAT
|
Health Risk |
Likely pathogenic |
Moyamoya angiopathy, Moyamoya angiopathy |
| RS1639171700 |
MFN2
|
Health Risk |
Conflicting classifications of pathogenicity |
Charcot-Marie-Tooth disease type 2A2, Charcot-Marie-Tooth disease type 2 |
| RS1639197832 |
MFN2
|
Health Risk |
Likely pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2A2 |
| RS1639199557 |
MFN2
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS1639200820 |
MFN2
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Global developmental delay |
| RS1639253483 |
HSPG2
|
Health Risk |
Conflicting classifications of pathogenicity |
— |
| RS1639294429 |
HSPG2
|
Health Risk |
Pathogenic |
— |
| RS1639299226 |
MFN2
|
Health Risk |
Likely pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS1639390139 |
MFN2
|
Health Risk |
Conflicting classifications of pathogenicity |
Charcot-Marie-Tooth disease type 2, Hereditary motor and sensory neuropathy with optic atrophy |
| RS1639458746 |
PUM1
|
Health Risk |
Pathogenic |
Spinocerebellar ataxia 47, Spinocerebellar ataxia 47 |
| RS1639468949 |
FUCA1
|
Health Risk |
Likely pathogenic |
Fucosidosis, Abnormality of the nervous system |
| RS1639470403 |
FUCA1
|
Health Risk |
Likely pathogenic |
Fucosidosis, Fucosidosis |
| RS1639559794 |
AK2
|
Health Risk |
Likely pathogenic |
Severe combined immunodeficiency disease, Severe combined immunodeficiency disease |
| RS1639603168 |
FUCA1;LOC126805661
|
Health Risk |
Likely pathogenic |
— |
| RS1639604269 |
FUCA1
|
Health Risk |
Conflicting classifications of pathogenicity |
Fucosidosis, Fucosidosis |
| RS1639662557 |
FUCA1
|
Health Risk |
Pathogenic |
Fucosidosis, Fucosidosis |
| RS1639662981 |
FUCA1
|
Health Risk |
Pathogenic |
Fucosidosis, Fucosidosis |
| RS1639663980 |
FUCA1
|
Health Risk |
Pathogenic |
Fucosidosis, Fucosidosis |
| RS1639666186 |
FUCA1
|
Health Risk |
Pathogenic |
Fucosidosis, Fucosidosis |
| RS1639669672 |
FUCA1
|
Health Risk |
Pathogenic/Likely pathogenic |
Fucosidosis, Fucosidosis |
| RS1639761448 |
TNFRSF9
|
Health Risk |
Pathogenic/Likely pathogenic |
TNFRSF9-related disorder, TNFRSF9-related disorder |
| RS1639840705 |
TNFRSF9
|
Health Risk |
Likely pathogenic |
— |
| RS1640042273 |
PUM1
|
Health Risk |
Likely pathogenic |
— |
| RS1640047087 |
PUM1
|
Health Risk |
Pathogenic |
— |
| RS1640237880 |
LCK
|
Health Risk |
Pathogenic |
Severe combined immunodeficiency due to LCK deficiency, Severe combined immunodeficiency due to LCK deficiency |
| RS1640240555 |
GJA4
|
Health Risk |
Pathogenic |
Cutaneous venous malformation, Hepatic hemangioma |
| RS1640240931 |
LCK
|
Health Risk |
Likely pathogenic |
Severe combined immunodeficiency due to LCK deficiency, Severe combined immunodeficiency due to LCK deficiency |
| RS1640406042 |
LCK
|
Health Risk |
Pathogenic |
Severe combined immunodeficiency due to LCK deficiency, Severe combined immunodeficiency due to LCK deficiency |
| RS1640610158 |
AK2
|
Health Risk |
Pathogenic |
Reticular dysgenesis, Reticular dysgenesis |
| RS1640658015 |
PUM1
|
Health Risk |
Likely pathogenic |
Spinocerebellar ataxia 47, Spinocerebellar ataxia 47 |
| RS1640875002 |
NMNAT1
|
Health Risk |
Likely pathogenic |
Leber congenital amaurosis 9, Leber congenital amaurosis 9 |
| RS1640875786 |
NMNAT1
|
Health Risk |
Likely pathogenic |
Leber congenital amaurosis 9, Leber congenital amaurosis 9 |
| RS1641167602 |
PEX14
|
Health Risk |
Likely pathogenic |
Peroxisome biogenesis disorder, complementation group K |
| RS1641316046 |
NPHP4
|
Health Risk |
Likely pathogenic |
Senior-Loken syndrome 4, Senior-Loken syndrome 4 |
| RS1641387459 |
RERE
|
Health Risk |
Conflicting classifications of pathogenicity |
Inborn genetic diseases, RERE-related disorder |
| RS1641418583 |
RERE
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurodevelopmental disorder, Neurodevelopmental disorder with or without anomalies of the brain |
| RS1641438649 |
CAMTA1
|
Health Risk |
Pathogenic |
Cerebellar dysfunction with variable cognitive and behavioral abnormalities, Cerebellar dysfunction with variable cognitive and behavioral abnormalities |
| RS1641481122 |
RERE
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS1641554114 |
SAMHD1
|
Health Risk |
Pathogenic |
Aicardi-Goutieres syndrome 5, Aicardi-Goutieres syndrome 5 |
| RS1641565884 |
RERE
|
Health Risk |
Likely pathogenic |
Autism spectrum disorder, Autism spectrum disorder |
| RS1641657166 |
VPS13D
|
Health Risk |
Pathogenic |
— |
| RS1641698007 |
ATAD3A
|
Health Risk |
Likely pathogenic |
Harel-Yoon syndrome, Harel-Yoon syndrome |
| RS1641702737 |
NMNAT1
|
Health Risk |
Likely pathogenic |
Leber congenital amaurosis 9, Leber congenital amaurosis 9 |